What is GOSS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GOSS?

P/E (TTM) is n/a and 52-week range is $9.10 to $309.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GOSS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GOSS?

The company profile lists revenue (TTM) near $79M, net income (TTM) near $-18.62B, EPS (TTM) near $-0.56 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Gossamer Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 488.9M shares outstanding, ISIN US38341P1021 when available from company profile and filing metadata.

Gossamer Bio Inc

$GOSS

Health Care · Biotechnology

IR Run Scenarios

$9.31

-5.77%

Gossamer Bio Inc

$GOSS

Health Care · Biotechnology

IR Run Scenarios

$9.31

-5.77%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Employees

162

Website

www.gossamerbio.com/

IPO

2019-02-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US38341P1021

Headquarters

San Diego, California, US

Shares outstanding

488.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

85.72%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Employees

162

Website

www.gossamerbio.com/

IPO

2019-02-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)